484 Mrv0541 02231214432D 17 19 0 0 0 0 999 V2000 5.0992 -1.2518 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0 2.2020 -0.3499 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 3.6702 -0.4268 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 2.8694 0.8062 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 6.5511 -0.4554 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 6.5511 1.2518 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 1.6500 0.2633 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.0625 0.9777 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.9557 -0.0143 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 4.3846 -0.0143 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 5.0992 -0.4268 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 5.8136 -0.0143 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 4.3846 0.8107 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 5.8136 0.8107 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 5.0992 1.2232 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 7.2986 -0.0314 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 7.2986 0.8279 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1 11 1 0 0 0 0 2 7 1 0 0 0 0 2 9 1 0 0 0 0 3 9 1 0 0 0 0 3 10 1 0 0 0 0 4 8 1 0 0 0 0 4 9 2 0 0 0 0 5 12 2 0 0 0 0 5 16 1 0 0 0 0 6 14 2 0 0 0 0 6 17 1 0 0 0 0 7 8 1 0 0 0 0 10 11 2 0 0 0 0 10 13 1 0 0 0 0 11 12 1 0 0 0 0 12 14 1 0 0 0 0 13 15 2 0 0 0 0 14 15 1 0 0 0 0 16 17 2 0 0 0 0 M END > T3D3487 > t3db > BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12 > InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17) > XYLJNLCSTIOKRM-UHFFFAOYSA-N > C11H10BrN5 > 292.135 > 291.011957992 > 5 > 25.74393406400084 > 1 > 2 > 0 > 1 > 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine > 1.27 > 1.3715845303333332 > -3.28 > 0 > 3 > 1 > 8.31635216122091 > 62.2 > 68.4944 > 1 > 1 > 1.54e-01 g/l > brimonidine > 0 > T3D3487 > Brimonidine > 59803-98-4 > 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; Alphagan; Brimonidina; Brimonidine tartrate; Brimonidinum; Bromoxidine; Mirvaso > Organic Compound; Amine; Organobromide; Amide; Bromide Compound; Drug; Adrenergic alpha-Agonist; Antihypertensive Agent; Metabolite; EENT Preparation; Synthetic Compound; Adrenergic alpha-2 Receptor Agonist $$$$